Characterization of human papillomavirus subtype 72b.

Johansson, Hanna K; Kravtchenko, Evgenia; Forslund, Ola

Published in:
Genome Announcements

DOI:
10.1128/genomeA.01320-14

2014

Link to publication

Citation for published version (APA):

General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal

Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
Characterization of Human Papillomavirus Subtype 72b

Hanna Johansson, Evgenia Kravtchenko, Ola Forslund
Department of Laboratory Medicine, Medical Microbiology, Lund University, Malmö, Sweden

We report the characterization of human papillomavirus (HPV) subtype 72b of the genus *Alphapapillomavirus* isolated from an oral rinse sample of a healthy woman. The HPV72b L1 open reading frame (ORF) was 90.2% identical to that of HPV72, indicating a subtype close to the border of a novel HPV type.

In an oral rinse sample from a 44-year-old woman we identified a novel sub-genomic Forslund Antonsson primer (FAP)-fragment, FA171, with closest sequence identity to HPV72 (1). After cloning of its complete genome we determined that the L1 open reading frame (ORF) was 90.2% identical to that of HPV72 (genus *Alphapapillomavirus*). Therefore, it was labeled as subtype HPV72b of HPV72, originally isolated from an oral papillomatous lesion of an HIV positive patient (2).

The complete genome of HPV72b (8,098 bp) was obtained using the PrimeSTAR GXL DNA polymerase kit (TaKaRa Bio, Shiga, Japan). Briefly, 2.5 μL purified DNA (Magna LC, Roche) was amplified in 25 μL containing 1 × PrimeSTAR GXL buffer, 200 μM of each dNTP, 0.2 μM of each primer (fwd 5'-TGA CTA CAA GCA AAC ACA GTT GCT T-3' and rev 5'-ACA GAT ATA TTG TCC CGG CTG TC-3') and 0.625 U PrimeSTAR GXL DNA polymerase. Amplification was performed for 45 cycles at 98°C for 10 s, 60°C for 15 s, and 68°C for 8 min in a thermocycler (Mastercycler Eppendorf, Germany). The amplicon was cloned using the TOPO TA cloning kit (Invitrogen, Carlsbad, CA) and sequenced using primer-walking (Eurofins, Germany).

A novel HPV type shares less than 90% similarity to the closest papillomavirus (PV) type in the L1 ORF (3). Pairwise comparisons between L1 ORFs of HPV72b and HPV72 (second ATG) (2) demonstrated 90.2% nucleotide (nt) identity, whereas the other ORFs showed identities less than 90% (E6: 85.0%, E7: 85.4%, E1: 89.2%, E2: 85.5%, E4: 80.6%, E5: 69.5%, L2: 87.2%) and URR 78.6%. The overall similarity between HPV72b and HPV72 was 89.2%, E2: 85.5%, E4: 80.6%, E5: 69.5%, L2: 87.2%) and URR 78.6%. The overall similarity between HPV72b and HPV72 was 89.2%, E2: 85.5%, E4: 80.6%, E5: 69.5%, L2: 87.2%) and URR 78.6%.

The putative E6 proteins contained two zinc-finger domains (CxxC[x]29CxxC) (5) separated by 39 amino acids. One zinc-finger domain was present in the E7 protein. The LxCxE-motif (binding site for the pRB) (6) was not observed in the E7 protein as the cysteine was substituted for a serine in the corresponding site, LxSxE, identical to that of HPV72.

The putative E1 protein did not exhibit the conserved ATP-binding site (GPPDTGKS) (7, 8), instead GPSNTGKS was found. The initiation codon of the putative start of E4 ORF was absent, as the ATG codon was changed to ACG.

**Nucleotide sequence accession number.** The complete genomic sequence of HPV72b is available in GenBank under the accession no. KJ145795.

**ACKNOWLEDGMENTS**

This project was supported by BioCARE, a Strategic Research Program at Lund University, Sweden, and by the Swedish Cancer Society.

**REFERENCES**


